Abstract:AIDS Research and Human RetrovirusesVol. 30, No. S1 Towards Broadly Neutralizing Antibody InductionInduction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 VaccineesMichael Anthony Moody, David Easterhoff, Thaddeus C. Gurley, John F. Whitesides, Dawn J. Marshall, Andrew Foulger, Krissey E. Lloyd, Robert Parks, Justin Pollara, Ryan Duffy, Shaunna Shen, Jerome H. Kim, Nelson L. Michael, Merlin L. Robb, Robert J. O'Connell, Sandhya Vasan, Jean-Louis Excler, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, Donald Francis, Carter Lee, Thomas B. Kepler, S. Munir Alam, Guido Ferrari, David C. Montefiori, Hua-Xin Liao, Georgia D. Tomaras, and Barton F. HaynesMichael Anthony MoodyDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, David EasterhoffDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Thaddeus C. GurleyDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, John F. WhitesidesDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Dawn J. MarshallDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Andrew FoulgerDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Krissey E. LloydDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Robert ParksDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Justin PollaraDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Ryan DuffyDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Shaunna ShenDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Jerome H. KimUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Nelson L. MichaelUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Merlin L. RobbUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Robert J. O'ConnellAFRIMS, Bangkok, ThailandSearch for more papers by this author, Sandhya VasanAFRIMS, Bangkok, ThailandSearch for more papers by this author, Jean-Louis ExclerUS Military HIV Research Program, Rockville, MD, United StatesSearch for more papers by this author, Supachai Rerks-NgarmThai Ministry of Public Health, Nonthaburi, ThailandSearch for more papers by this author, Jaranit KaewkungwalMahidol University, Bangkok, ThailandSearch for more papers by this author, Punnee PitisuttithumMahidol University, Bangkok, ThailandSearch for more papers by this author, Sorachai NitayaphanAFRIMS, Bangkok, ThailandSearch for more papers by this author, Faruk SinangilGlobal Solutions for Infectious Diseases, South San Francisco, CA, United StatesSearch for more papers by this author, Donald FrancisGlobal Solutions for Infectious Diseases, South San Francisco, CA, United StatesSearch for more papers by this author, Carter LeeGlobal Solutions for Infectious Diseases, South San Francisco, CA, United StatesSearch for more papers by this author, Thomas B. KeplerBoston University, Boston, MA, United StatesSearch for more papers by this author, S. Munir AlamDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Guido FerrariDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, David C. MontefioriDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Hua-Xin LiaoDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, Georgia D. TomarasDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this author, and Barton F. HaynesDuke University Medical Center, Duke Human Vaccine Institute, Durham, NC, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5057a.abstractAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees." AIDS Research and Human Retroviruses, 30(S1), p. A36FiguresReferencesRelatedDetailsCited byThe Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States24 May 2017 | Vaccines, Vol. 5, No. 2 Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Michael Anthony Moody, David Easterhoff, Thaddeus C. Gurley, John F. Whitesides, Dawn J. Marshall, Andrew Foulger, Krissey E. Lloyd, Robert Parks, Justin Pollara, Ryan Duffy, Shaunna Shen, Jerome H. Kim, Nelson L. Michael, Merlin L. Robb, Robert J. O'Connell, Sandhya Vasan, Jean-Louis Excler, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, Donald Francis, Carter Lee, Thomas B. Kepler, S. Munir Alam, Guido Ferrari, David C. Montefiori, Hua-Xin Liao, Georgia D. Tomaras, and Barton F. Haynes.Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees.AIDS Research and Human Retroviruses.Oct 2014.A36-A36.http://doi.org/10.1089/aid.2014.5057a.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download

Type-specific and Cross-Reactive Neutralizing Antisera Against HIV Elicited by V3-peptide Heptalysine Octomers.

HIV Type 1 B′/C Recombinant (CRF07_BC) in Virologic Noncontrollers Elicits Neutralizing Antibodies Against Heterologous but Not Autologous Viruses

Sequence Characteristics of Hiv-1 B' Envelope Proteins and Its Potential Correlation with Broadly Neutralizing Activity

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Two Partially Overlapping Antiviral Peptides from the External Portion of HIV Type 1 Glycoprotein 41, Adjoining the Transmembrane Region, Affect the Glycoprotein 41 Fusion Domain

Combined Approach of Vaccine and Antiviral Drugs Can Achieve Better Protection in Nhp Model Against Heterologous Shiv Challenges

Induction of Broadly Neutralizing Antibodies to Hiv-1 Via Dna Motif Immunization

Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans

Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees

Epitopes Immediately below the Base of the V3 Loop of Gp120 As Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-infected Individuals.

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of Gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-infected Individual.

Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies

Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.

Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

WHO Working Group on Characterization of HIV-Related Retroviruses: Criteria for Characterization and Proposal for a Nomenclature System

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors

Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies